SITE002-0071

SITE002 (USA) › SITE002-0071

SITE002-0071

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2025-11-23

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 230); relationship: not assessed

mild assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 210); relationship: not assessed

moderate assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 195); relationship: NOT RELATED

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-10 (study day 70); relationship: not assessed

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 5); relationship: RELATED

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-06-03 (study day 2); relationship: not assessed

mild assessed

Data queries

1

AE Fatigue (grade 1) for SITE002-0071 has onset 2025-12-08, 1 d before first dose on 2025-12-09. Confirm onset date or record as pre-treatment.

onset_on[Fatigue 2025-12-08] open